Trump says ceasefire with Iran still 'in effect'

 United States President Donald Trump told ABC News that the ceasefire with Iran remains "in effect," following what the US military described as "self-defense" strikes against the country's military sites.

"It's just a love tap," Trump said of Washington's strikes in the phone interview. When asked by ABC News' Rachel Scott whether that meant the ceasefire is over, Trump said, "No, no, the ceasefire is going. It's in effect."

The two sides gave contradictory accounts of Thursday's flare-up, with the US military saying it fended off "unprovoked" strikes, while Iranian media reported the assault as retaliation for a US attack on an Iranian oil tanker.

https://breakingthenews.net/Article/Trump-says-ceasefire-with-Iran-still-'in-effect'/66248267

Tandem Diabetes beats, reiterates guidance

 

Tandem Diabetes Care beats EPS and revenue estimates with Q1 2026 non-GAAP EPS -$0.30 and revenue $247.2M, reaffirms 2026 revenue and margin guidance

• Q1 2026 revenue was $247.2M, increasing 5% year over year.
• Non-GAAP EPS was -$0.30 in Q1 2026, improving 55% year over year.
• Q1 2026 net loss reported totaled $20.4M during the quarter.

https://finviz.com/quote?t=TNDM&p=d#google_vignette

Oncology Institute beats, reaffirms guidance

 

Oncology Institute posts Q1 2026 EPS -$0.02 (+90% YoY) on revenue $147.4M (+41% YoY), beating EPS and revenue estimates

• Q1 2026 net loss narrows to $2.5M, as reported by the company
• Company reaffirms 2026 guidance and projects Q2 2026 Adjusted EBITDA between $(1) million and $1 million

https://finviz.com/quote?t=TOI&p=d

BioLife beats, reaffirms guidance

 

BioLife Solutions beats Q1 2026 EPS and revenue estimates with non-GAAP EPS $0.02, revenue $27.5M, reiterates 2026 guidance

• Non-GAAP EPS $0.02 increased 300% YoY in Q1 2026, exceeding analyst estimates.
• Q1 2026 revenue was $27.5M, up 15% YoY, also above revenue estimates.
• GAAP EPS for Q1 2026 was $0.02, and the company reiterated full-year 2026 financial guidance.

https://finviz.com/quote?t=BLFS&p=d

AMN beats, eyes lower 2Q revenue

 

AMN Healthcare Q1 2026 non-GAAP EPS $2.10 (+367% YoY), revenue $1.4B (+100% YoY), both beat estimates

• Q1 2026 revenue $1.38B and adjusted EPS $2.10 both exceeded company guidance.
• Quarter performance was driven by substantial labor disruption revenue, which made a significant contribution to first-quarter 2026 results.
• For the second quarter, AMN issued guidance calling for modest year-over-year revenue declines.

https://finviz.com/quote?t=AMN&p=d

argenx Q1 2026 EPS $5.52 beats by $0.07 as revenue $1.3B misses

 

argenx Q1 2026 EPS $5.52 beats by $0.07 as revenue $1.3B misses by about $20M on strong VYVGART

• VYVGART sales reached $1.3B in Q1 2026, up 63% year over year.
• argenx reported Q1 2026 profit of $366M, reflecting improved earnings versus the prior-year period.
• Company reiterates May 10, 2026 PDUFA date for seronegative gMG.

https://finviz.com/quote?t=ARGX&p=d

Corvus misses EPS but beats revenue estimates, cash runway into Q2 2028

 

Corvus Pharmaceuticals reports Q1 2026 non-GAAP EPS -$0.15 (-15% YoY) on revenue $0, misses EPS but beats revenue estimates

• Q1 2026 net loss totaled $13.7M, with no revenue reported in the quarter.
• Ended Q1 2026 with $236.7M in cash, providing runway into Q2 2028.
• Advanced soquelitinib into Phase 2 trial for atopic dermatitis during the quarter.
• Plans additional Phase 2 soquelitinib studies in hidradenitis suppurativa and asthma following atopic dermatitis trial initiation.

https://finviz.com/quote?t=CRVS&p=d